The Mascoma management team comprises an experienced group of leaders who understand the complex challenges involved in developing and introducing innovative technologies into new and growing markets such as fuel ethanol. This team is ideally suited to manage the multi-faceted challenges of simultaneously discovering, developing, and deploying Mascoma’s innovative technologies.
William J. Brady, Jr. has served as our President, Chief Executive Officer and a director since he joined our company in January 2010. Previously, Mr. Brady was Executive Vice President of Cabot Corporation, or Cabot, a specialty chemical company, from 2004 to 2009. Throughout his twenty-three year experience, Mr. Brady held numerous positions at Cabot in the United States and Japan, including General Manager of the Carbon Black business. Under his leadership, the business completed significant expansions in China and Brazil, and executed a major global initiative in energy efficiency. In addition, he led the commercialization of two start-up businesses at Cabot in ink jet colorants and elastomer composites. Mr. Brady currently serves on our board of directors and is Chairman of the Board of our affiliate, Frontier Renewable Resources, LLC. In addition, he is Chairman of the Washington D.C. based Advanced Ethanol Council, or AEC, which working on the commercialization of advanced and cellulosic ethanol development by establishing public policies and expanding the market for ethanol. Mr. Brady is also a member of the Board of Trustees at the University of Scranton. Mr. Brady is a graduate of the University of Scranton with a B.S. in Chemistry and received his M.B.A. from Fairleigh Dickinson University.
David A. Arkowitz has served as our Chief Financial Officer since joining our company in June 2011, and as our Treasurer and Secretary since July 2011. Prior to joining our company, Mr. Arkowitz served as Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer at AMAG Pharmaceuticals, Inc. a public biopharmaceutical company, from 2007 to 2011. Prior to joining AMAG, Mr. Arkowitz served as Chief Financial Officer and Treasurer at Idenix Pharmaceuticals, Inc., a public biopharmaceutical company, from 2003 to 2007. Prior to his tenure at Idenix, Mr. Arkowitz was with Merck & Co. Inc., or Merck, a public pharmaceutical company, for over thirteen years, where he served as Vice President and Controller of the U.S. sales and marketing division from 2002 to 2003, as Controller of the global research and development division from 2000 to 2002, and as Vice President of Finance and Business Development of the Canadian subsidiary of Merck from 1997 to 2000. Mr. Arkowitz served on the board of directors and was the Chairman of the Audit Committee of Aegerion Pharmaceuticals, Inc., a pharmaceutical company, from 2007 to 2009, and served on the board of directors and was the Chairman of the Audit Committee of ImpactRx, Inc., a company that analyzes the impact of promotion on physicians’ prescribing behavior, from 2005 to 2009. Mr. Arkowitz holds a B.A. in Mathematics from Brandeis University and an M.B.A. from Columbia University.
Stephen R. Kennedy has served as our Executive Vice President, Research & Development since joining our company in May 2011. His most recent experience prior to joining our company was at the Massachusetts Institute of Technology in Cambridge, Massachusetts from October 2010 to May 2011, where he held appointments in the Department of Chemical Engineering as Interim Executive Director of the Novartis/MIT Center for Continuous Manufacturing and in the Department of Biology/Center for Biomedical Innovation, where his responsibilities included scale-up of fungible fuel technology. Mr. Kennedy spent 18 years in the biopharmaceutical industry at Genzyme Corporation, or Genzyme, where he held senior positions in process development from 1992 to 1998, led development of manufacturing operations in the United States, France and Belgium from 1998 to 2004, and served as Senior Vice-President, Biologics Technical Operations from 2004 until 2010. Prior to his tenure at Genzyme, Mr. Kennedy spent 12 years at Eastman Kodak’s BioProducts Division and Genencor International, or Genencor, in research, development and technology transfer. He played a key role in the successful start-up of Genencor, leading manufacturing process development activities in Finland from 1990 to 1992. Mr. Kennedy holds a B.S. in Chemical Engineering from the University of Michigan, an M.S. in Chemical Engineering from the University of Rochester and an M.B.A. from Boston University.
Alan H. Belcher has served as our Senior Vice President Operations since 2007. Prior to joining our company, from 2006 to 2007, Mr. Belcher served as Executive Vice President of Technology of Ethanex Energy Inc., a company developing manufacturing technology and operations in the ethanol industry. From 2001 to 2006, Mr. Belcher served as Vice President Project Development with Delta-T Corporation, an engineering and construction company servicing the ethanol alcohol markets. While with Iogen Corporation, a Canada-based firm specializing in cellulosic ethanol, Mr. Belcher served as Vice President, Engineering and was responsible for leading the scale-up of Canada’s first biomass-to-ethanol process to a commercial scale. Mr. Belcher began his career with the Corn Products Division of CPC International, a refiner and processor of corn-based food additives and sweeteners, and later joined Fluor Daniel, an engineering, procurement, construction and maintenance services company. Mr. Belcher received a B.S. in Chemical Engineering from the University of Waterloo in Waterloo, Ontario and an M.B.A. from the Tuck School of Business at Dartmouth College, and is a licensed professional engineer.
® All rights reserved. Mascoma Corporation 2009